Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Stagezero Life Sciences Ltd. (SZLSF : OTC)
 
 • Company Description   
StageZero Life Sciences Ltd is dedicated to the early detection of cancer and multiple disease states through whole blood. The company's test consists of Aristotle(R), a multi-cancer panel for simultaneously screening for cancers from a single sample of blood. StageZero Life Sciences Ltd, formerly known as GeneNews Ltd., is based in TORONTO, ON.

Number of Employees: 51

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.07 Daily Weekly Monthly
20 Day Moving Average: 3,704 shares
Shares Outstanding: 100.73 (millions)
Market Capitalization: $7.45 (millions)
Beta: 0.94
52 Week High: $0.50
52 Week Low: $0.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.38% -3.28%
12 Week -57.40% -55.15%
Year To Date -67.87% -62.54%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
70 East Beaver Creek Road Unit 30
-
Richmond Hill,A6 L4B 3B2
CAN
ph: 905-209-2030
fax: 905-209-2031
rgreco@stagezerols.com http://www.stagezerolifesciences.com
 
 • General Corporate Information   
Officers
James Howard-Tripp - Chief Executive Officer and Chairman
Leslie Auld - Chief Financial Officer
Rory Riggs - Director
Harry Glorikian - Director
Garth MacRae - Director

Peer Information
Stagezero Life Sciences Ltd. (BJCT)
Stagezero Life Sciences Ltd. (CADMQ)
Stagezero Life Sciences Ltd. (APNO)
Stagezero Life Sciences Ltd. (UPDC)
Stagezero Life Sciences Ltd. (IMTIQ)
Stagezero Life Sciences Ltd. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 852540301
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 100.73
Most Recent Split Date: 9.00 (0.13:1)
Beta: 0.94
Market Capitalization: $7.45 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.63
Price/Cash Flow: -
Price / Sales: 1.91
EPS Growth
vs. Year Ago Period: 87.50%
vs. Previous Quarter: 80.00%
Sales Growth
vs. Year Ago Period: -46.67%
vs. Previous Quarter: -12.05%
ROE
03/31/22 - -364.40
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -88.55
12/31/21 - -169.49
09/30/21 - -159.40
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - 0.57
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - 0.41
Operating Margin
03/31/22 - -190.21
12/31/21 - -279.14
09/30/21 - -217.06
Net Margin
03/31/22 - -20.01
12/31/21 - -147.77
09/30/21 - -108.96
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -113.53
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - 0.05
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - 8.02
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - 0.15
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - 13.17
 

Powered by Zacks Investment Research ©